UBS Group
GLUE icon

UBS Group’s Monte Rosa Therapeutics GLUE Stock Holding History

UBS Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.51M Buy
152,620
+29,620
+24% +$566K ﹤0.01% 4759
2025
Q4 		$1.93M Buy
123,000
+50,905
+71% +$686K ﹤0.01% 5010
2025
Q3 		$534K Sell
72,095
-36,146
-33% -$191K ﹤0.01% 6043
2025
Q2 		$488K Buy
108,241
+16,727
+18% +$74.6K ﹤0.01% 6029
2025
Q1 		$425K Buy
91,514
+32,115
+54% +$197K ﹤0.01% 5977
2024
Q4 		$412K Buy
59,399
+34,066
+134% +$256K ﹤0.01% 5982
2024
Q3 		$134K Buy
25,333
+2,039
+9% +$10.3K ﹤0.01% 6153
2024
Q2 		$87.1K Sell
23,294
-17,879
-43% -$91.2K ﹤0.01% 6282
2024
Q1 		$290K Buy
41,173
+3,225
+8% +$19.1K ﹤0.01% 5593
2023
Q4 		$214K Buy
37,948
+14,639
+63% +$57.4K ﹤0.01% 5741
2023
Q3 		$112K Sell
23,309
-466
-2% -$3K ﹤0.01% 5763
2023
Q2 		$163K Buy
23,775
+13,369
+128% +$86.5K ﹤0.01% 5620
2023
Q1 		$81.1K Buy
10,406
+1,159
+13% +$8.06K ﹤0.01% 6094
2022
Q4 		$70.4K Buy
+9,247
New +$77K ﹤0.01% 6442
2022
Q2 		– Sell
-29,408
Closed -$412K – 10546
2022
Q1 		$412K Buy
29,408
+26,148
+802% +$363K ﹤0.01% 4826
2021
Q4 		$67K Buy
+3,260
New +$68.3K ﹤0.01% 6660

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

UBS Group's GLUE Position: Q1 2026 in Review

UBS Group increased its Monte Rosa Therapeutics (GLUE) stake by 24% in Q1 2026, buying an estimated $566K and bringing the position to 152,620 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #4759.

UBS Group first reported a position in GLUE in Q4 2021 and has held it in 16 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • UBS Group held 152,620 shares of Monte Rosa Therapeutics worth $2.51M as of Q1 2026.
  • UBS Group bought 29,620 Monte Rosa Therapeutics shares in Q1 2026, an estimated $566K.
  • Monte Rosa Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4759 holding.
  • UBS Group first reported a position in Monte Rosa Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.